pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

Sponsored

12 Questions with Sam Dixey

Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.

Market Access

Sponsored

Company Profile: Acumetis

Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity.

Market Access

Patient pathway activation and industry’s role in enabling a...

News

Vertex gets paediatric FDA okay for Casgevy gene therapy

For the first time, children in the US as young as two with blood disorders sickle cell disease and beta thalassaemia are eligible for gene therapy.

News

Colorado's pathfinder medicine price-cap move stalls

A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on blockbuster immunology drug Enbrel.

Featured Content

Digital

Sponsored

12 Questions with Sam Dixey

Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.

Market Access

Patient pathway activation and industry’s role in enabling a...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Vertex gets paediatric FDA okay for Casgevy gene therapy

For the first time, children in the US as young as two with blood disorders sickle cell disease and beta thalassaemia are eligible for gene therapy.

News

Colorado's pathfinder medicine price-cap move stalls

A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on blockbuster immunology drug Enbrel.

News

Two women sit side by side in support of each other, one in a white coat and beret, the other in red

NICE guidance calls for quicker diagnosis of PMOS

Women with polyendocrine metabolic ovarian syndrome (PMOS) should be diagnosed sooner and be offered an annual review, according to new NICE guidance.

News

Ipsen's M&A team strikes again, adding Memo in $700m deal

Ipsen will pay up to €700m to take control of Memo Therapeutics and its drug for BK polyomavirus, which can lead to the failure of kidney transplants.

Views & Analysis

Digital

Sponsored

12 Questions with Sam Dixey

Find out more about Sam Dixey, Head of Medical Affairs Innovation and Technology (MAIT) at LUCENT Biopharma.

Digital

Changing Faces: Digital and supplier hires, May 2026

The digital, supplier, CRO, and medtech services sectors continued to see a steady flow of leadership changes during the month of May.

Market Access

A dynamic moment for pharma pricing: Insights from PPIC

At PPIC in Basel, pharma pricing experts discussed how policy changes and AI advances are altering the dynamics of pharmaceutical pricing and access.

R&D

Separating scientific risk assessment & consumer perception

In pharmaceutical development, conclusions are built on structured laboratory investigations and reproducible data, rather than simple classification.